. 2022 Dec 30;43(6):1140–1149. doi: 10.19852/j.cnki.jtcm.20221230.001

Table 7.

Effect of Naoluoxintong and its split prescriptions on the cerebral infarction area in the experimental rats ($\bar{x}$ ± s)

Group	n	Cerebral infarction area	VEGFA	VEGFR2	CD31
S	6	0.00±0.00	16.33±1.21	11.83±1.17	2.18±0.11
M	6	25.77±1.36^a	18.50±1.38	15.5±1.05	5.83±0.30^a
NMDP	6	12.38±1.10^b	39.50±3.62^b	37.17±2.32^b	19.14±1.91^b
NLXT	6	13.80±1.63^b	39.17±2.79^b	35.83±2.32^b	19.63±0.44^b
YQ	6	23.31±0.84^c	21.50±1.87^b	21.17±1.94^bc	13.80±0.92^bc
HXTL	6	21.45±1.60^bc	23.17±1.48^bc	23.17±1.47^bc	11.95±0.43^bc

Notes: S: Sham group (saline, 14 d); M: Model group (saline, 14 d); NMDP: Nimodiping group (8.1 mg/kg, 14 d); NLXT: Naoluoxintong group (7.2 g/kg, 14 d); YQ: Yiqi group (2.7 g/kg, 14 d); HXTL: Huoxuetongluo group (4.5 mg/kg, 14 d). VEGFA: vascular endothelial growth factor A; VEGFR2: vascular endothelial growth factor receptor 2; CD31: platelet endothelial cell adhesion molecule-1.^aP < 0.01 vs S; ^bP < 0.01 vs M; ^cP < 0.01 vs NLXT.